摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1'-O-acetylsucrose | 63648-82-8

中文名称
——
中文别名
——
英文名称
1'-O-acetylsucrose
英文别名
Fruf1Ac(b2-1a)Glc;[(2S,3S,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)-2-[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxolan-2-yl]methyl acetate
1'-O-acetylsucrose化学式
CAS
63648-82-8
化学式
C14H24O12
mdl
——
分子量
384.337
InChiKey
LAXOWOVJHZHMHS-YYAHPEQVSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    -3.7
  • 重原子数:
    26
  • 可旋转键数:
    7
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.93
  • 拓扑面积:
    196
  • 氢给体数:
    7
  • 氢受体数:
    12

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    1'-O-acetylsucrose 在 phosphate buffer 、 yeast α-glucosidase 作用下, 反应 48.0h, 生成 1-O-acetylfructose
    参考文献:
    名称:
    Carrea, Giacomo; Riva, Sergio; Secundo, Francesco, Journal of the Chemical Society. Perkin transactions I, 1989, p. 1057 - 1061
    摘要:
    DOI:
  • 作为产物:
    描述:
    2,2,2-三氯乙酸乙酯蔗糖 在 protease N 作用下, 以 N,N-二甲基甲酰胺 为溶剂, 反应 48.0h, 以36%的产率得到1'-O-acetylsucrose
    参考文献:
    名称:
    Carrea, Giacomo; Riva, Sergio; Secundo, Francesco, Journal of the Chemical Society. Perkin transactions I, 1989, p. 1057 - 1061
    摘要:
    DOI:
点击查看最新优质反应信息

文献信息

  • Radio-opaque compounds, compositions containing same and methods of their synthesis and use
    申请人:Pathak P. Chandrashekhar
    公开号:US20050036946A1
    公开(公告)日:2005-02-17
    Radio-opaque biodegradable compositions are formed by modifying terminal groups of synthetic and natural biodegradable polymers such as polylactones with iodinated moieties. The biodegradable property of the compositions renders them suitable for use in medical field such as drug delivery, imaging. Compounds disclosed in this invention exist as neat liquid. Certain compositions disclosed in this invention form hydrophobic iodine rich domains when dissolved in water, such domains provide better contrasting properties as well as ability to dissolve hydrophobic bioactive drugs. Certain iodinated moieties disclosed in the invention are capable of cross linking natural proteins in situ in presence of suitable catalysts and co-catalysts.
    放射不透明的可生物降解组合物是通过修改合成和天然可生物降解聚合物(如聚乳酸酯)的末端基团与化基团形成的。这些组合物的生物降解性使它们适用于医疗领域,如药物输送、成像等用途。本发明中披露的化合物存在于纯净液体中。本发明中披露的某些组合物在中溶解时形成疏富区域,这些区域提供更好的对比性能以及溶解疏生物活性药物的能力。本发明中披露的某些化基团能够在适当催化剂和共催化剂存在的情况下交联天然蛋白质。
  • [EN] BRANCHED PEG MOLECULES AND RELATED COMPOSITIONS AND METHODS<br/>[FR] MOLÉCULES DE PEG RAMIFIÉ, COMPOSITIONS ET PROCÉDÉS ASSOCIÉS
    申请人:PHASERX INC
    公开号:WO2018126084A1
    公开(公告)日:2018-07-05
    Disclosed are branched PEG molecules, including branched PEG-lipids and branched-PEG proteins, as well as related compositions and methods for making branched PEG molecules. Also disclosed are related compositions, systems, and methods for in vivo delivery of therapeutic and diagnostic agents.
    揭示了分支聚乙二醇(PEG)分子,包括分支PEG-脂质和分支PEG-蛋白质,以及制备分支PEG分子的相关组合物和方法。还公开了相关的组合物、系统和方法,用于体内传递治疗和诊断试剂。
  • [EN] GEL FORMULATIONS FOR GUIDING RADIOTHERAPY<br/>[FR] FORMULES DE GEL POUR LE GUIDAGE D'UNE RADIOTHÉRAPIE
    申请人:UNIV DANMARKS TEKNISKE
    公开号:WO2014187962A1
    公开(公告)日:2014-11-27
    The present invention describes an X-ray contrast composition for local administration, wherein the X-ray contrast composition exhibits contrast properties and wherein at least 60% of an administrated amount of said X-ray contrast composition remains more than 24 hours within 10 cm from an injection point when the X-ray contrast composition is administrated to a human or animal body.
    本发明描述了一种用于局部给药的X射线对比剂组合物,其中X射线对比剂组合物具有对比性能,当将X射线对比剂组合物注入人体或动物体内时,所注入的X射线对比剂组合物中至少60%在注射点10厘米内停留超过24小时。
  • [EN] DISSACHARIDE FORMULATIONS FOR CONTROLLED DRUG RELEASE<br/>[FR] FORMULATIONS DE DISACCHARIDES POUR LA LIBÉRATION CONTRÔLÉE DE MÉDICAMENTS
    申请人:UNIV DENMARK TECH DTU
    公开号:WO2020249801A1
    公开(公告)日:2020-12-17
    The present invention relates to a composition comprising non-water soluble dissacharides and oil, a solvent and at least one pharmaceutical ingredient, wherein the composition contains at least two compounds selected from saccharides and lipid oils such as lactose octabenzoate Methyl hepta-O-isobutyryl-α,β-lactoside, α,β-Lactose octa para-iodobenzoate, 3-iodobenzyl hepta-O-isobutyryl-α,β-lactoside, lactose octapropionate, lactose octaisobutyrate, sucrose octabenzoate, glycerol trihexanoate, Glycerol trioctanoate, Glycerol tridecanoate, Lipiodol, ethyl myristate, ethyl palmitate, ethyl oleoate and wherein the composition is a liquid before administration into the human or animal body and increases in viscosity by more than 2,000 centipoise (cP) after administration.
    本发明涉及一种组合物,包括不溶于双糖和油、溶剂和至少一种药物成分,其中该组合物含有至少两种从糖类和脂肪油中选择的化合物,例如乳糖苯甲酸酯、甲基庚烯基七-O-异丁酰-α,β-乳糖苷、α,β-乳糖八对苯甲酸酯、3-碘苯甲基七-O-异丁酰-α,β-乳糖苷、乳糖丙酸酯、乳糖异丁酸酯、蔗糖苯甲酸酯、三己酸甘油酯、三辛酸甘油酯三癸酸甘油酯、利油、肉豆蔻酸乙酯棕榈酸乙酯油酸乙酯,其中该组合物在注入人体或动物体内之前为液体,并在注入后黏度增加超过2,000厘泊(cP)。
  • [EN] COMPOSITIONS SUITABLE FOR CONTROLLED RELEASE OF THE HORMONE GnRH AND ITS ANALOGS<br/>[FR] COMPOSITION ASSURANT LA LIBERATION REGULEE DE L'HORMONE GNRH ET DE SES ANALOGUES
    申请人:SOUTHERN BIOSYSTEMS, INC.
    公开号:WO1998053837A1
    公开(公告)日:1998-12-03
    (EN) A liquid composition for the controlled release of gonodotropin releasing hormone (GnRH) or its analogs is provided that includes: (i) a non-polymeric, non-water soluble liquid carrier material (HVLCM) or viscosity of at least 5,000 cP at 37 °C that does not crystallize neat under ambient or physiological conditions; and (ii) GnRH or analogs thereof.(FR) L'invention concerne une composition liquide assurant la libération régulée d'une hormone libérant de la gonadolibérine (GnRH), ou de ses analogues, laquelle composition contient: (i) un excipient liquide non soluble dans l'eau et non polymère qui possède une viscosité au moins égale à 5 000 cP à 37 ° C, et qui ne se cristallise pas nettement sous des conditions ambiantes ou physiologiques; et (ii) la GnRH ou des analogues de celle-ci.
    提供一种用于控制释放促性腺激素释放激素(GnRH)或其类似物的液体组合物,包括:(i)一种非聚合物、非溶性液体载体材料(HVLCM)或在37℃下粘度至少为5,000 cP,不会在常温或生理条件下净结晶;以及(ii)GnRH或其类似物。
查看更多